MedTrace Logo

Treatment of Failing Blebs With Ranibizumab

NCT00570726 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-10-15

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.

Conditions

  • Glaucoma, Open-Angle
  • Failing Bleb Following Trabeculectomy

Interventions

DRUG

Ranibizumab (Lucentis)

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The New York Eye & Ear Infirmary

    lead OTHER

Principal Investigators

  • Jeffrey Liebmann, MD · Robert Ritch, MD, LLC.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570726 on ClinicalTrials.gov